Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Inman, Robert D ^a   Chiu, Basil ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NAFAMSTAT MESILATE; ANTIINFECTIVE AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL INCLUSION; CHLAMYDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HISTOPATHOLOGY; IN VITRO STUDY; JOINT SWELLING; MALE; NONHUMAN; OPTICAL DENSITY; PATHOGEN LOAD; PHASE CONTRAST MICROSCOPY; RAT; REACTIVE ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; ANIMAL; ARTHRITIS; CHLAMYDIASIS; DRUG EFFECT; LEWIS RAT; MICROBIOLOGY; PATHOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, REACTIVE; CHLAMYDIA INFECTIONS; GUANIDINES; INCLUSION BODIES; MALE; RATS; RATS, INBRED LEW; SERINE PROTEINASE INHIBITORS;

EID: 84862313123     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3886     Document Type: Article

References (20)

1. Carter JD, Inman RD. Chlamydia-induced reactive arthritis: Hidden in plain sight. Best Pract Res Clin Rheumatol 2011, 25:359-374. 10.1016/j.berh.2011.05.001, 22100286.
2. Inman RD, Chiu B. Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis. J Clin Invest 1998, 102:1776-1782. 10.1172/JCI2983, 509126, 9819362.
3. Inman RD, Chiu B. Cytokine profiles in the joint define pathogen clearance and severity in Chlamydia-induced arthritis. Arthritis Rheum 2006, 54:499-507. 10.1002/art.21643, 16447224.
4. Chang JH, Lee IS, Kim HK, Cho YK, Park JM, Kim SW, Choi MG, Chung IS. Nafamostat for prophylaxis against post-endoscopic retrograde cholangiopancreatography pancreatitis compared with gabexate. Gut Liver 2009, 3:205-210. 10.5009/gnl.2009.3.3.205, 2852705, 20431747.
5. Cao YG, Chen YC, Hao K, Zhang M, Liu XQ. An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull 2008, 31:1985-1989. 10.1248/bpb.31.1985, 18981560.
6. Inman RD, Chiu B. Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis. Arthritis Res Ther 2009, 11:19-27.
7. Li Q, Nacion K, Bu H, Lin F. The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis. Am J Path 2009, 175:661-667. 10.2353/ajpath.2009.081093, 2715286, 19608865.
8. Inman RD. Infection and spondyloarthritis. Nature Rheumatol 2006, 2:163-169.
9. Inman RD, Stone MA. Reactive arthritis: aetiology and pathogenesis. Rheumatology 2011, 1101-1112. Philadelphia: Elsevier, Mosby, Hochberg MC, 5.
10. Inman RD. Reactive Arthritis. Rheumatologist 2010, 4:24-33.
11. Bonte LRL, Davis-Gorman G, Stahl GL, McDonagh PF. Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Cir Physiol 2008, 294:H1282-H1290.
12. Ishizaki M, Tanaka H, Kajiwara D, Toyohara T, Wakahara K, Inagaki N, Nagai H. Nafamostat mesylate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. J Pharmacol 2008, 108:355-363.
13. Phongsisay V, Susski K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, Hirata K, Shinoda M, Yuki N. Complement inhibitor prevents disruption of sodium clusters in a rabbit model of Guillain-Barre Syndrome. J Neuroimmunol 2008, 205:101-104. 10.1016/j.jneuroim.2008.09.016, 18973956.
14. Schwertz H, Carter JM, Russ M, Schubert S, Schlitt A, Buerke U, Schmidt M, Hillen H, Werdan K, Buerke M. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition. J Cardiovasc Pharmacol 2008, 52:151-160. 10.1097/FJC.0b013e318180188b, 18670364.
15. Ino Y, Sato T, Koshiyama Y, Suzuki K, Oda M, Iwaki M. Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation. Gen Pharmsc 1987, 18:513-516.
16. Miyagi S, Okada A, Oikawa K, Sato A, Fujimori K, Satomi S. Effects of serine protease inhibitor and prostaglandin I2 on liver transplantation from non-heart beating rat donors. Transplant Proceed 2008, 40:2152-2155.
17. Hagiwara S, Iwasaka H, Matumoto S, Noguchi T. Nafamostat mesylate inhibits High-Mobility Group Box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7. Shock 2007, 27:429-435. 10.1097/01.shk.0000239778.25775.ad, 17414427.
18. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesylate with gemcitabine for pancreatic cancer targeting NFκB activation. Anticancer Res 2009, 29:3137-3178.
19. Uwagawa T, Li Z, Chang Z, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL, Chiao PJ. Mechanisms of synthetic serine protease inhibitor (FUT-175) mediated cell death. Cancer 2007, 109:2142-2153. 10.1002/cncr.22658, 17410536.
20. Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Valeriano J, Stanich JA, Oszust C, Gerard HC, Hudson AP. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis. Arthritis Rheum 2010, 62:1290-1297. 10.1002/art.27383, 20461780.